 |
|
|
| |
ARO-HSD, an investigational RNAi therapeutic, demonstrates reduction in ALT and hepatic HSD17B13 mRNA and protein in patients with NASH or suspected NASH
|
| |
| |
AASLD 2021 Nov 12-15
Lung Yi Mak1, Man Fung Yuen1, Christian Schwabe2, Ki Tae Yoon3, Jeong Heo4, Russell Scott5, Jeon-Hoon Lee6, Jung Il Lee7, Young Oh Kweon8, Martin Weltman9, Stephen A. Harrison10, Brent A. Neuschwanter-Tetri11 , Kenneth Cusi12, Rohit Loomba13, Eric Garcia-Medel14, Min Yi14, Javier San Martin14, Marco Wong14, James Hamilton14, Ed Gane15
1 Queen Mary Hospital, The University of Hong Kong, Hong Kong; 2 New Zealand Clinical Research, Auckland, New Zealand; 3 Pusan National University Yangsan Hospital, Yangsan, Republic of Korea; 4 Pusan National University and Medical Research Institute, Busan, Republic of Korea; 5 Lipid and Diabetes Research, Christchurch Hospital, Christchurch, New Zealand; 6 Seoul National University Hospital, Seoul, Republic of Korea; 7 Gangnam Severance Hospital, Seoul, Republic of Korea; 8 Kyungpook National University, Daegu, Republic of Korea; 9 Nepean Hospital, Penrith, Australia; 10 Pinnacle Clinical Research Center, San Antonio, United States; 11 Saint Louis University School of Medicine, St. Louis, United States; 12 University of Florida, Gainesville, United States; 13 NAFLD Research Center, UCSD, Division of Gastroenterology, La Jolla, United States; 14 Arrowhead Pharmaceuticals, Pasadena, USA; 15 University of Auckland, Auckland, New Zealand.
|
| |
|
|
|
|
|
